PDCD1 and renal cell carcinoma: Numerous tumors, including advanced metastatic melanoma, colorectal cancer, non-small-cell lung cancer (NSCLC), and renal cell carcinoma (RCC), show promising responses to anti-PD-1 monoclonal antibody treatment [4,5,7,8].